YouTube Facebook LinkedIn Google+ Twitter Xingrss  

GSK Launches Hostile Takeover Bid for Human Genome Sciences


May 10, 2012 | GlaxoSmithKline has launched a hostile takeover bid for long-time partner Human Genome Sciences worth $2.6 billion, or $13/share. A poll of analysts revealed that they expected sale price will be around $15/share. The board of Human Genome turned down a bid from GSK last month. Baltimore Sun
View Next Related Story
15 Biotechs to Watch | Sep 22, 2014
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.